Santen Pharmaceutical
Update in progress4536.T (Tokyo)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - General
Santen Pharmaceutical Co., Ltd. develops, manufactures, and markets medicines and medical devices for eye diseases worldwide, including Japan, China, Asia, Europe, the Middle East, Africa, and beyond. Its portfolio includes tafluprost/timolol and latanoprost for glaucoma and ocular hypertension, ciclosporin for allergic conjunctivitis, epinastine, and a range of other ophthalmic products such as netarsudil/latanoprost, sepetaprost, and omidenepag isopropyl. The company is based in Osaka and was founded in 1890.
Company score
- Sentiment
- 0.29
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.26
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketTokyo (JPX)
- LocationJapan
- CEOMr. Takeshi Ito
- Founded1890
- Employees3,968
- Websitewww.santen.com/en
Identifiers
- ISINJP3336000009